Tandem Diabetes (TNDM) Tops Q4 EPS by 7c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus

Note: EPS may not be comparable

Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($1.23), $0.07 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $40 million versus the consensus estimate of $37.99 million.

2018 Guidance

For the year ending December 31, 2018, the Company is providing the following guidance on a GAAP basis:

1. Sales are estimated to be in the range of $132 million to $140 million

• Sales for the first quarter of 2018 are estimated to be 18 percent - 19 percent of annual sales

2. Operating margin is estimated to be in the range of negative 40 percent to negative 35 percent, which includes:

• Approximately $4.0 million to $5.0 million in non-cash, stock-based compensation expense
• Approximately $7.0 million to $8.0 million of depreciation and amortization

GUIDANCE:

Tandem Diabetes sees FY2018 revenue of $132-140 million, versus the consensus of $132.53 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary